NEUROTERA: For the placing on the market of new therapeutic agents against ocular and cerebral comorbidities associated with paramyloidosis (Q2907213): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Import item from Portugal) |
(Changed an Item) |
||||||||||||||
| Property / thematic objective | |||||||||||||||
| Property / thematic objective: Research and innovation / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / date of last update | |||||||||||||||
23 May 2023
| |||||||||||||||
| Property / date of last update: 23 May 2023 / rank | |||||||||||||||
Normal rank | |||||||||||||||
Revision as of 20:09, 23 May 2023
Project Q2907213 in Portugal
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | NEUROTERA: For the placing on the market of new therapeutic agents against ocular and cerebral comorbidities associated with paramyloidosis |
Project Q2907213 in Portugal |
Statements
891,220.51 Euro
0 references
1,136,307.6 Euro
0 references
78.43 percent
0 references
16 August 2016
0 references
15 February 2020
0 references
BSIM THERAPEUTICS, S.A.
0 references
Q2988326 (Deleted Item)
0 references
23 May 2023
0 references
Identifiers
POCI-01-0247-FEDER-003431
0 references